24/7 Market News Snapshot 06 May, 2025 – CorMedix Inc. (NASDAQ:CRMD)

May 6, 2025

DENVER, Colo., 06 May, 2025 (www.247marketnews.com) – (Nasdaq:CRMD) are discussed in this article.
CorMedix Inc. (Nasdaq:CRMD), a biopharmaceutical company focused on developing therapies for serious medical conditions, has recently garnered significant attention as its stock demonstrates remarkable performance, seeing an increase of over 21.36%. Beginning the trading day at $9.59, shares have climbed to $10.96, a rise reflecting heightened investor interest and optimism surrounding the company’s future prospects.

This surge coincides with CorMedix’s announcement of its financial results for the first quarter of 2025, where the company recorded net revenues of approximately $39.1 million, primarily attributed to robust sales of its lead product, DefenCath®, in outpatient dialysis markets. A stark contrast to previous losses, CorMedix reported a net income of $20.6 million, translating to $0.32 per share. Additionally, adjusted EBITDA for the quarter stood at $23.6 million, showcasing efficient operational performance amid strategic cost management.

With the inpatient sales team now fully operational, CorMedix successfully doubled shipments of DefenCath in institutional settings over the last three months and anticipates sustained growth driven by an ongoing Phase 3 study aimed at reducing Central Line Associated Blood Stream Infections in adult patients receiving Total Parenteral Nutrition.

As of March 31, 2025, the company holds $77.5 million in cash and short-term investments, ensuring adequate funding for strategic initiatives over the coming year. Management projects net sales ranging from $62 million to $70 million for the first half of 2025, further underscoring a positive outlook based on favorable order trends. CorMedix remains dedicated to advancing therapeutic solutions to improve patient outcomes while continuing to enhance its position in the competitive biotech landscape.

Related news for (CRMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.